Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials


1 Kaiser Permanente, San Francisco Medical Center and Division of Research, San Francisco, CA, USA; 2 Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA; 3 Brigham and Women’s Hospital, Harvard Medical School, MA, Boston, USA; 4 National Heart Centre Singapore, Singapore, Singapore and Duke-National University of Singapore, Singapore, Singapore; 5 Duke University Medical Center, Durham, NC, USA; 6 National University of Cordoba, Cordoba, Argentina; 7 Yale School of Medicine, New Haven, CT, USA; 8 Northwestern Memorial Hospital, Chicago, IL, USA; 9 Erasmus University Medical Center, Rotterdam, The Netherlands; 10 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; and 11 Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Received 2 May 2023; revised 10 May 2023; accepted 11 May 2023; online publish-ahead-of-print 7 June 2023

Aims
Patients with heart failure experience a high burden of symptoms and physical limitations, and poor quality of life. Dapagliflozin reduces heart failure hospitalization and cardiovascular death in patients with reduced, mildly reduced, and preserved ejection fractions. We examined the effects of dapagliflozin on health status, measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), across the full spectrum of left ventricular ejection fraction (LVEF).

Methods and results
Participant-level data were pooled from the DAPA-HF and DELIVER trials. Both trials were randomized, global, double-blind, placebo-controlled trials of patients with symptomatic heart failure and elevated natriuretic peptides. DAPA-HF and DELIVER included patients with LVEF ≤40% and LVEF >40%, respectively. KCCQ was evaluated at randomization and at 4 and 8 months post-randomization; the effect of dapagliflozin versus placebo on KCCQ total symptom score (TSS) was a pre-specified secondary outcome in both trials. Interaction testing was performed to assess potential heterogeneity in the effects of dapagliflozin versus placebo on KCCQ-TSS, clinical summary score (CSS), overall summary score (OSS), and physical limitation score (PLS), by continuous LVEF using restricted cubic splines. Responder analyses examining the proportion of patients with meaningful deterioration (≥5 point decline) and meaningful improvements (≥5 point increase) in KCCQ-TSS was assessed across LVEF categories. Of 11 007 randomized participants, 10 238 (93%) had full data on KCCQ-TSS at randomization. Benefits of dapagliflozin versus placebo on KCCQ-TSS, -CSS, -OSS, -PLS, at 8 months were consistent across the full range of LVEF ($p_{interaction} = 0.19, 0.10, 0.12, 0.10, respectively$). In responder analyses, fewer dapagliflozin- versus placebo-treated patients had clinically meaningful deteriorations in KCCQ-TSS (overall: 21% vs. 23%; LVEF ≤40%: 21% vs. 29%; LVEF 41–60%: 21% vs. 26%; LVEF >60%: 22% vs. 27%). A greater proportion of patients randomized to dapagliflozin experienced at least small improvements in KCCQ-TSS (overall: 50% vs. 45%; LVEF ≤40%: 48% vs. 41%; LVEF 41–60%: 51% vs. 49%; LVEF >60%: 53% vs. 45%). The effects of dapagliflozin versus placebo on clinically meaningful deteriorations and improvements in...
Introduction

Patients with heart failure (HF) experience a high burden of symptoms, physical limitations, and poor quality of life regardless of left ventricular ejection fraction (LVEF). Improving health status and quality of life is a central goal in the treatment of HF. Importantly, many therapies have demonstrated most pronounced benefits on clinical and patient reported outcomes in patients with HF with reduced ejection fraction, with relative attenuation in clinical benefits at higher LVEF. Contemporary descriptions of the relationship between health status and ejection fraction have been underexplored.

Dapagliflozin reduces HF hospitalization and cardiovascular death and improves quality of life in patients with reduced, mildly reduced, and preserved ejection fractions and is guideline-recommended for the treatment of HF across the spectrum of ejection fraction. Whether favourable effects on health status and quality of life are present equally across the LVEF spectrum has not been as fully elucidated. Therefore, we examined the effects of dapagliflozin on health status, measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), across the full spectrum of LVEF using pooled, participant-level data from the DAPA-HF and DELIVER randomized clinical trials.

Methods

We used a participant-level, pooled dataset of the DAPA-HF and DELIVER trials. DAPA-HF was a double-blind, placebo-controlled, global trial which randomized 4744 ambulatory patients with symptomatic HF, elevated natriuretic peptide and LVEF ≤40% to receive either dapagliflozin 10 mg daily or placebo. DELIVER similarly randomized 6263 participants to dapagliflozin 10 mg daily versus placebo, but enrolled patients with HF and mildly reduced or preserved ejection fraction (LVEF >40%). With the exception of included LVEF ranges, trial inclusion and exclusion criteria were similar. The primary efficacy endpoint in both trials was a composite of the time-to-first worsening HF event (defined as hospitalization for HF or an urgent HF visit requiring intravenous HF therapies) or cardiovascular death.

The KCCQ was completed by trial participants and evaluated at randomization, 4 and 8 months in both trials. The KCCQ is a 23-item, self-administered HF-specific instrument that quantifies symptoms (frequency, severity and recent change), physical function, quality of life, and social function over the prior 2 weeks. Domains include the total symptom score (TSS), physical limitation score (PLS), clinical summary score (CSS), and overall summary score (OSS); KCCQ has been validated in patients across the spectrum of LVEF. Scores are transformed to a range of 0–100, in which higher scores reflect better health status. Change in KCCQ-TSS from randomization to 8 months was a pre-specified secondary outcome in both trials.

In participant-level pooled analyses of DAPA-HF and DELIVER, dapagliflozin improved all key domains of health status across the full range of LVEF. Clinically meaningful improvements in health status were also observed consistently across LVEF, including in those with LVEF >60%.

Conclusions

In participant-level pooled analyses of DAPA-HF and DELIVER, dapagliflozin improved all key domains of health status across the full range of LVEF. Clinically meaningful improvements in health status were also observed consistently across LVEF, including in those with LVEF >60%.

Clinical Trial Registration: NCT03036124 and NCT03619213.

Keywords

Heart failure ● Quality of life ● Ejection fraction

Results

Of 11 007 patients randomized, 10 238 (93%) had full data on KCCQ-TSS at randomization. Patients had a mean age of...
Health status with dapagliflozin across LVEF

69 ± 10 years, 35% were female and 3.5% were Black. Median LVEF was 44% (interquartile range [IQR] 34–55%); 4747 (43%), 4865 (44%) and 1395 (13%) patients had LVEF ≥40%, 41–60%, and >60%, respectively. Median KCCQ-TSS at randomization was 75 (IQR 57–90). Patients with LVEF ≤40% were less symptomatic by KCCQ-TSS scores at randomization (77; IQR 58–92), compared with patients with LVEF 41–60% (73; IQR 55–88) and LVEF >60% (73; IQR 54–88; p < 0.001). Similar trends were observed across additional KCCQ summary scores (online supplementary Table S1).

In a pooled analysis including participants in DAPA-HF and DELIVER, participants treated with dapagliflozin had a significant improvement in mean KCCQ-TSS at 4 months (mean difference: +1.8 [95% confidence interval [CI] +1.1, +2.4]) and 8 months (mean difference: +2.5 [95% CI +1.8, +3.2]) post-randomization (Figure 1). Results were consistent across additional KCCQ domains (Figure 1) and most key subgroups of interest (Figure 2). Mean improvements in KCCQ-TSS at 8 months in those treated with dapagliflozin vs. placebo were greater in those with type 2 diabetes (+3.4; 95% CI +2.3, +4.6) compared to those without (+1.8; 95% CI +0.9, +2.7; p interaction = 0.026). Dapagliflozin improved health status compared with placebo from randomization to 8 months across KCCQ-TSS, -CSS, -OSS, -PLS domains in a manner that was consistent across the full range of ejection fraction, including among those with LVEF >60% (p interaction = 0.19, 0.10, 0.12, 0.10, respectively; Figure 3).

In responder analyses, fewer dapagliflozin- versus placebo-treated patients had clinically meaningful deteriorations (≥5 point decline) in KCCQ-TSS by 8 months post-randomization (21% vs. 29%, odds ratio [OR] 0.71; 95% CI 0.64–0.79; p < 0.001). Results were consistent across patients with LVEF ≤40% (31% vs. 29%, OR 0.66; 95% CI 0.57–0.77), LVEF 41–60% (21% vs. 29%, OR 0.76; 95% CI 0.65–0.89), and LVEF >60% (22% vs. 27%, OR 0.78; 95% CI 0.58–1.04; p interaction = 0.20).

A greater proportion of patients randomized to dapagliflozin experienced large (≥15 point increase) improvements in KCCQ-TSS by 8 months post-randomization (28% vs. 25%, OR 1.15; 95% CI 1.04–1.27; p = 0.005). Large improvements in health status among dapagliflozin- versus placebo-treated patients were consistent across LVEF (p interaction = 0.94), including patients with LVEF ≤40% (24% vs. 21%, OR 1.19; 95% CI 1.03–1.39), LVEF 41–60% (31% vs. 29%, OR 1.07; 95% CI 0.93–1.24), and LVEF

© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
>60% (32% vs. 26%, OR 1.31; 95% CI 0.99–1.73). The effects of dapagliflozin versus placebo on small (≥5 point increase) and moderate (≥10 point increase) in health status by KCCQ-TSS were also consistent across the full spectrum of LVEF ($p_{interaction}$ = 0.64 and 0.97, respectively; Figure 4). Results were largely similar when considering KCCQ-CSS, -OSS, and -PLS (Table 1). Across the LVEF spectrum, the number needed to treat to affect an at least 5 point improvement at 8 months in health status assessed by KCCQ-TSS, -CSS, -OSS, and -PLS was 20, 17, 24, and 22, respectively.

Among those who experienced HF hospitalization during the timeframe in which KCCQ measurements were available, health status, as measured by KCCQ, declined on average ∼10 points prior to HF hospitalization, particularly evident in the 3 months preceding the event. Results were qualitatively similar in those with LVEF ≤40% (DAPA-HF) and LVEF >40% (DELIVER) (Figure 5).

### Discussion

In participant-level pooled analyses of DAPA-HF and DELIVER, dapagliflozin improved multiple domains of health status as measured by KCCQ, regardless of LVEF. Significant improvements in health status were observed consistently across the full range of LVEF, including in those with LVEF >60%. Patients randomized to dapagliflozin were less likely to experience meaningful deteriorations in health status and more likely to experience small, moderate, and large improvements in health status than those randomized to placebo; these beneficial effects were also observed consistently across the full range of LVEF.

We observed a steep decline in KCCQ preceding a HF hospitalization, with health status worsening starting as early as 3 months prior to HF hospitalization; trends were similar in DAPA-HF and DELIVER. These data are similar to those from other published trials in HF and suggest that clinical deteriorations may be preceding by large changes in symptomatic burden and health status. These data suggest that prospective, frequent assessments of patient-reported health status might aid in early identification, management, and triage of patients at risk for clinical decompensation, a hypothesis which requires further study.

Importantly, we observed no attenuation in benefit of dapagliflozin versus placebo on health status as measured by
Figure 3: Treatment effects of dapagliflozin versus placebo on mean 8-month change in health status. Treatment effects shown as the placebo-controlled change in health status from randomization to month 8 in Kansas City Cardiomyopathy Questionnaire domains including total symptom score, clinical summary score, overall summary score, and physical limitation score across the spectrum of ejection fraction modelled as a continuous variable.

Various KCCQ domains among patients at the highest end of LVEF; numerically, mean improvements in health status were greater at the higher end of the LVEF spectrum. These patients experienced an especially high burden of health status impairment at baseline, on average greater than that of patients with reduced LVEF.7 These impairments in patients with the highest LVEF may be the result of higher burden of cardiovascular and non-cardiovascular comorbidities among this population, and it has been postulated that therefore health status in this group may be less modifiable by traditional HF therapies.8 However, this was not apparent for the sodium–glucose cotransporter 2 inhibitor dapagliflozin in this pooled analysis of DAPA-HF and DELIVER.

Of note, our results differ from those previously reported utilizing participant-level pooled data from EMPEROR-Reduced and EMPEROR-Preserved in which improvements in KCCQ appeared to be attenuated in patients at the highest ranges of LVEF.9,10 Similar attenuation in benefit was seen with respect to total HF hospitalizations in these trials; subsequent detailed analyses dispute these discordant findings in the EMPORER programme as possibly a chance finding.11 Importantly, presented data from a participant-level pooled analysis of the two more modestly sized DEFINE-HF (LVEF ≤40%)12 and PRESERVED-HF (LVEF ≥45%)13 trials demonstrated consistent benefits of dapagliflozin on shorter term (3 months) health status across the spectrum of LVEF, with no suggestion of attenuated benefit at higher LVEF.14 These benefits, numerically larger than those seen in the present analysis, were observed in a highly symptomatic contemporary US population with greater health status burden at baseline than in patients enrolled in DAPA-HF and DELIVER.

While mean changes in KCCQ were relatively modest, we observed that the proportion of patients experiencing at least moderate (≥10 point increases) and large (≥15 point increases) in health status was significantly greater in those randomized to dapagliflozin versus placebo; results were consistent across the full range of LVEF. The use of patient-reported health status is increasingly recognized as a clinically important endpoint15; in HF, regulatory guidance includes patient-reported health status endpoints as potentially providing evidence of effectiveness of a therapy (in the absence of important safety considerations).16 However, challenges remain in defining the minimum magnitude of benefit considered to be clinically meaningful17; while some studies suggest even small changes (5+ points) may be clinically important,18 moderate and large changes as defined in this analysis are generally considered meaningful. Therefore, the greater proportion of moderate to large health gains in those treated with dapagliflozin, across the spectrum of ejection fraction, including those with LVEF >60%, further adds to the evidence supporting the efficacy of this therapy in HF.
**Table 1** Responder analyses in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains at 8 months across additional KCCQ domains

<table>
<thead>
<tr>
<th>KCCQ domain</th>
<th>Deterioration (5+ point decline)</th>
<th>At least small improvement (5+ points)</th>
<th>At least moderate improvement (10+ points)</th>
<th>Large improvement (15+ points)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(95% CI)</td>
<td>pInteraction</td>
<td>(95% CI)</td>
<td>pInteraction</td>
</tr>
<tr>
<td>KCCQ-CSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>0.75</td>
<td>0.67, 0.83</td>
<td>0.41</td>
<td>1.26</td>
</tr>
<tr>
<td>LVEF ≤40%</td>
<td>0.74</td>
<td>0.64, 0.86</td>
<td>1.39</td>
<td>1.23</td>
</tr>
<tr>
<td>LVEF 41–60%</td>
<td>0.73</td>
<td>0.62, 0.86</td>
<td>1.09</td>
<td>0.95</td>
</tr>
<tr>
<td>LVEF &gt;60%</td>
<td>0.81</td>
<td>0.60, 1.09</td>
<td>1.48</td>
<td>1.15</td>
</tr>
<tr>
<td>KCCQ-OSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>0.76</td>
<td>0.68, 0.84</td>
<td>0.82</td>
<td>1.18</td>
</tr>
<tr>
<td>LVEF ≤40%</td>
<td>0.73</td>
<td>0.63, 0.84</td>
<td>1.25</td>
<td>1.10</td>
</tr>
<tr>
<td>LVEF 41–60%</td>
<td>0.78</td>
<td>0.67, 0.92</td>
<td>1.05</td>
<td>0.92</td>
</tr>
<tr>
<td>LVEF &gt;60%</td>
<td>0.79</td>
<td>0.58, 1.06</td>
<td>1.39</td>
<td>1.08</td>
</tr>
<tr>
<td>KCCQ-PLS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>0.85</td>
<td>0.77, 0.94</td>
<td>0.36</td>
<td>1.21</td>
</tr>
<tr>
<td>LVEF ≤40%</td>
<td>0.75</td>
<td>0.65, 0.87</td>
<td>1.22</td>
<td>1.07</td>
</tr>
<tr>
<td>LVEF 41–60%</td>
<td>1.00</td>
<td>0.86, 1.17</td>
<td>1.11</td>
<td>0.97</td>
</tr>
<tr>
<td>LVEF &gt;60%</td>
<td>0.76</td>
<td>0.57, 1.02</td>
<td>1.59</td>
<td>1.22</td>
</tr>
</tbody>
</table>

CI, confidence interval; CSS, clinical summary score; LVEF, left ventricular ejection fraction; OR, odds ratio; OSS, overall summary score; PLS, physical limitation score.
This study has some limitations. While the pooling of DAPA-HF and DELIVER was pre-specified in the regulatory statistical analysis plan, changes in health status were not pre-specified in the hierarchy of outcomes. We relied on LVEF that was site-reported, and core laboratory standardization was not undertaken in either trial. KCCQ was assessed through 8 months in both trials and not at later time points.

Conclusion

In participant-level pooled analyses of DAPA-HF and DELIVER, dapagliflozin improved multiple domains of health status regardless of LVEF. Clinically meaningful improvements in health status were observed consistently across the full range of LVEF, including in those with LVEF >60%. These data support treatment with dapagliflozin to improve symptoms, physical limitations and quality of life in patients with HF regardless of baseline LVEF.

Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Conflict of interest: A.S.B. has no relevant disclosures. M.N.K. has received research grant support from AstraZeneca, and Boehringer Ingelheim; has served as a consultant or on an advisory board for Ailyam, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon, Merck (Diabetes and Cardiovascular), Novo Nordisk, Sanofi, Pharmacosmos and Vifor Pharma; has received other research support from AstraZeneca; and has received honoraria from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. M.V. has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participated in clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. B.L.C. has received consulting fees from Amgen, Cardurion, Corvia, and Novartis. C.S.P.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Alectin, Alleviant Medical, Allogya Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Proscienio Inc, Radcliffe Group Ltd., Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. A.F.H. has received research grants from American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Somalogic and Verily; and has served as a consultant or on the Advisory Board for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Eidos, Intercept, Merck, and Novartis. F.M. has received consultation fees and research grants from AstraZeneca, Biardila, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Gador, Milestone, Novartis, Pfizer, and St Lukes University. S.E.I. has served on clinical trial committees or as a consultant to AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lexicon, Merck, Pfizer, vTv Therapeutics, Abbott, and Esperion; and has given lectures sponsored by AstraZeneca and Boehringer Ingelheim. S.J.S. has received research grants from the National Institutes of Health (U54 HL160273, RO1 HL107577, RO1 HL127028, RO1 HL140731, RO1 HL149423), Alectinon, AstraZeneca, Corvia, Novartis, and Pfizer, and...
has received consulting fees from and consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Arix CV, Axon Therapies, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eisai, Eisai, Imara, Impulse Dynamics, GSK, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Sardocor, Shifamed, Tenax, Tenays, and United Therapeutics. R.A.D.B.'s institution has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardiokinetics Pharmaceuticals GmbH, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche; and has had speaker engagements with Abbott, AstraZeneca, Bayer, Bristol Myers Squibb, Novartis, and Roche. P.S.J.'s employer has been remunerated for his work on the DELIVER and DAPA-HF trials by AstraZeneca; and received consulting and speakers fees from Novartis, AstraZeneca, Boehringer Ingelheim, research funding from Boehringer Ingelheim, remuneration for clinical trial work from Novo Nordisk and Bayer. A.S.D. reports institutional grant support from Abbott, Alnylam, AstraZeneca, Bayer, Novartis, and consulting fees from Abbott, Alnylam, AstraZeneca, Avidity, Axon Therapeutics, Bayer, Biofourms, Boston Scientific, Cytokinetiks, GlaxoSmithKline, Merck, Novartis, Parxel, Regeneron, Roche, and Verily. M.P. is an employee and shareholder of AstraZeneca. A.M.L. is an employee of AstraZeneca. J.J.V.M. has received payments through Glasgow University for work on clinical trials, consulting and other activities from Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetiks, Dal-Cor, GSK, Ionis, KBP Biosciences, Novartis, Pfizer, Theracos, and personal lecture fees from the Corpus, Abbott, Hikma, Sun Pharmaceuticals, Medscape/Heart.org, Radcliffe Cardiology, Servier Director, Global Clinical Trial Partners (GCTP). S.D.S. has received research grants from Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetiks, Eisai, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, US2.AI, and has consulted for Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardio, Cardurion, Corvia, Cytokinetiks, Daiichi-Sankyo, GSK, Lilly, Merck, MyoKardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros. All other authors have nothing to disclose.

References